Table 1.
Patient characteristics of 177 patients undergoing 204 SRFA sessions of 238 nodules in the hepatic dome group and of 177 patients undergoing 281 SRFA sessions of 587 nodules in the control group
| Patient characteristics | Hepatic dome gr. | Control gr. |
|---|---|---|
| Age, median years (range) | 65 (7–87) | 64 (25–82) |
| Sex (female/male), n (%) | 48/129 (27.1/72.9) | 48/129 (27.1/72.9) |
| Tumor type, n (%) | ||
|
- HCC, n (%) - ICC, n (%) - Metastasis, n (%) • Colorectal, n (%) • Breast, n (%) • Melanoma, n (%) • Other, n (%) |
82 (46.3) 6 (3.4) 89 (50.3) 52 (65.8) 5 (6.3) 7 (8.9) 25 (19) |
80 (45.2) 11 (6.2) 86 (48.6) 47 (61.8) 3 (3.9) 4 (5.3) 32 (29) |
|
Cirrhosis, n (%) - Child A, n (%) - Child B, n (%) - Child C, n (%) |
68 (38.4) 60 (88.0) 7 (11.1) 1 (0.9) |
66 (37.3) 54 (81.1) 11 (16.8) 1 (2.1) |
| Tumor size, median (range) | 2.2 cm (0.5–10 cm) | 2.0 cm (0.5–13 cm) |
| Tumor number at beginning, n (range) | 2 (1–8) | 2 (1–9) |
| Total treated tumors, median (range) | 1 (1–4) | 2 (1–20) |
| Ablations per patient, n (range) | 1 (1–4) | 1 (1–10) |
| Patients receiving LTX, n (%) | 23 (13.1) | 24 (13.6) |
SRFA stereotactic radiofrequency ablation, HCC hepatocellular carcinoma, ICC intrahepatic cholangiocarcinoma, Child Child-Pugh score, LTX liver transplantation, gr. group